New York Times Makes Substantial Changes to Article That Glazed a Sleazy AI Startup: "Our Piece Should Have Included That Information"

"The New York Times published a profile of Medvi, portraying it as a successful AI-enabled startup, but failed to mention key legal and regulatory issues the company faces."

"Medvi has been warned by the FDA for alleged regulatory violations related to false and misleading marketing content, which was not included in the original article."

"The company is involved in multiple legal actions, including a class action lawsuit over alleged violations of California's spam laws, which the NYT did not initially report."

"Readers pointed out that Medvi engaged in dishonest marketing tactics, such as falsely claiming partnerships with doctors and manipulating images of patients."

Medvi, a startup offering AI-powered marketing for telehealth and weight loss drugs, was profiled by the New York Times as a success story. However, the article omitted significant details about the company's legal troubles, including a warning from the FDA regarding misleading marketing and a class action lawsuit for spam law violations. Readers highlighted these omissions, prompting the NYT to issue an editor's note acknowledging the need for a more comprehensive portrayal of Medvi's challenges and regulatory scrutiny.

Read at Futurism